S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.80 (-1.97%)
AAPL   171.51 (-1.52%)
MSFT   286.10 (-1.40%)
META   167.90 (-3.87%)
GOOGL   117.23 (-2.45%)
AMZN   138.16 (-2.91%)
TSLA   890.00 (-2.05%)
NVDA   178.28 (-5.03%)
NIO   19.08 (-4.17%)
BABA   89.63 (-1.22%)
AMD   95.92 (-4.50%)
T   18.43 (+0.00%)
MU   60.46 (-4.00%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.24 (-1.98%)
AMC   18.23 (-5.50%)
PYPL   96.62 (-3.24%)
PFE   49.25 (+1.38%)
NFLX   241.21 (-1.62%)
NYSE:USNA

USANA Health Sciences - USNA Stock Forecast, Price & News

$70.78
-2.00 (-2.75%)
(As of 08/19/2022 03:59 PM ET)
Add
Compare
Today's Range
$70.65
$72.99
50-Day Range
$65.12
$76.51
52-Week Range
$63.49
$103.95
Volume
2,297 shs
Average Volume
60,958 shs
Market Capitalization
$1.36 billion
P/E Ratio
15.59
Dividend Yield
N/A
Price Target
$77.33

USANA Health Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
9.3% Upside
$77.33 Price Target
Short Interest
Bearish
4.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
0.25mentions of USANA Health Sciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$577,480 Sold Last Quarter
Proj. Earnings Growth
8.54%
From $3.98 to $4.32 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

954th out of 1,116 stocks

Medicinals & Botanicals Industry

11th out of 14 stocks

USNA stock logo

About USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Jefferies Financial Group lowered USANA Health Sciences from a "hold" rating to an "underperform" rating and decreased their target price for the stock from $78.00 to $53.00 in a research report on Thursday, July 7th. StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 26th. Finally, DA Davidson reduced their price target on shares of USANA Health Sciences to $57.00 and set an "outperform" rating for the company in a research report on Wednesday, July 27th. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat, USANA Health Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $77.33.

USANA Health Sciences Stock Up 0.8 %

NYSE:USNA opened at $72.78 on Friday. USANA Health Sciences has a 52 week low of $63.49 and a 52 week high of $103.95. The firm has a market capitalization of $1.40 billion, a P/E ratio of 16.03 and a beta of 0.72. The company has a 50-day moving average price of $70.41 and a 200-day moving average price of $76.77.

USANA Health Sciences (NYSE:USNA - Get Rating) last released its earnings results on Tuesday, July 26th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.05). USANA Health Sciences had a return on equity of 22.49% and a net margin of 8.27%. During the same quarter in the previous year, the business earned $1.87 earnings per share. As a group, equities research analysts anticipate that USANA Health Sciences will post 3.98 EPS for the current year.

Insider Buying and Selling

In other USANA Health Sciences news, insider Paul A. Jones sold 5,029 shares of the company's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $70.00, for a total value of $352,030.00. Following the completion of the transaction, the insider now directly owns 3,682 shares in the company, valued at approximately $257,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other USANA Health Sciences news, insider Paul A. Jones sold 5,029 shares of the company's stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $70.00, for a total value of $352,030.00. Following the completion of the transaction, the insider now directly owns 3,682 shares in the company, valued at approximately $257,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brent Neidig sold 1,400 shares of the company's stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $70.93, for a total value of $99,302.00. Following the completion of the transaction, the insider now owns 1,406 shares of the company's stock, valued at $99,727.58. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,919 shares of company stock valued at $556,186. 0.36% of the stock is owned by corporate insiders.

Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Stock News Headlines

Expert Ratings for Usana Health Sciences
USANA Health Sciences Continues To Fall
USANA Legal Team Brings Home Two Awards
See More Headlines
Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

USNA Company Calendar

Last Earnings
7/26/2022
Today
8/19/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
Personal Products
Sector
Medical
CUSIP
90328M10
Employees
1,978
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.33
High Stock Price Forecast
$122.00
Low Stock Price Forecast
$53.00
Forecasted Upside/Downside
+9.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$116.50 million
Pretax Margin
12.47%

Debt

Sales & Book Value

Annual Sales
$1.19 billion
Cash Flow
$6.99 per share
Book Value
$21.03 per share

Miscellaneous

Free Float
19,129,000
Market Cap
$1.36 billion
Optionable
Optionable
Beta
0.72

Key Executives

  • Mr. Kevin G. Guest (Age 59)
    Chairman & CEO
    Comp: $1.52M
  • Mr. Jim  BrownMr. Jim Brown (Age 53)
    Pres
    Comp: $1M
  • Mr. G. Douglas Hekking (Age 52)
    Chief Financial Officer
    Comp: $764.98k
  • Mr. Walter  NootMr. Walter Noot (Age 56)
    Chief Operating Officer
    Comp: $739.06k
  • Mr. David Mulham (Age 62)
    Chief Sales Officer
    Comp: $828.52k
  • Dr. Myron W. WentzDr. Myron W. Wentz (Age 81)
    Founder & Chairman Emeritus
  • Dr. John Cuomo
    Exec. Director of Product Devel. & Technology
  • Dr. Robert A. SinnottDr. Robert A. Sinnott (Age 57)
    Chief Scientific Officer
  • Mr. Patrique Richards
    Exec. Director of Investor Relations & Bus. Devel.
  • Mr. P. Joshua FoukasMr. P. Joshua Foukas (Age 46)
    Chief Legal Officer, Gen. Counsel & Corp. Sec.













USNA Stock - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" USNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in USNA, but not buy additional shares or sell existing shares.
View USNA analyst ratings
or view top-rated stocks.

What is USANA Health Sciences' stock price forecast for 2022?

3 brokerages have issued 12 month target prices for USANA Health Sciences' shares. Their USNA share price forecasts range from $53.00 to $122.00. On average, they anticipate the company's stock price to reach $77.33 in the next year. This suggests a possible upside of 6.3% from the stock's current price.
View analysts price targets for USNA
or view top-rated stocks among Wall Street analysts.

How have USNA shares performed in 2022?

USANA Health Sciences' stock was trading at $101.20 at the beginning of 2022. Since then, USNA shares have decreased by 28.1% and is now trading at $72.78.
View the best growth stocks for 2022 here
.

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our USNA earnings forecast
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its earnings results on Tuesday, July, 26th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.05 by $0.05. USANA Health Sciences had a trailing twelve-month return on equity of 22.49% and a net margin of 8.27%. During the same period in the previous year, the company earned $1.87 earnings per share.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its board has initiated a share buyback program on Tuesday, February 9th 2021, which authorizes the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 8.2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's management believes its shares are undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its second quarter 2022 earnings guidance on Wednesday, August, 3rd. The company provided EPS guidance of $1.05-$1.05 for the period, compared to the consensus EPS estimate of $1.26. The company issued revenue guidance of $265.00 million-$265.00 million, compared to the consensus revenue estimate of $272.77 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.46%), Pzena Investment Management LLC (3.78%), State Street Corp (2.01%), Northern Trust Corp (0.64%), JPMorgan Chase & Co. (0.44%) and Principal Financial Group Inc. (0.40%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends
.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $72.78.

How much money does USANA Health Sciences make?

USANA Health Sciences (NYSE:USNA) has a market capitalization of $1.40 billion and generates $1.19 billion in revenue each year. The company earns $116.50 million in net income (profit) each year or $4.54 on an earnings per share basis.

How many employees does USANA Health Sciences have?

The company employs 1,978 workers across the globe.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The official website for the company is www.usana.com. The company can be reached via phone at (801) 954-7100, via email at investor.relations@usanainc.com, or via fax at 801-954-7300.

This page (NYSE:USNA) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.